By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > US court orders new FTC review of Illumina’s Grail deal
Stocks

US court orders new FTC review of Illumina’s Grail deal

News Room
Last updated: 2024/01/04 at 4:12 PM
By News Room
Share
3 Min Read
SHARE

© Reuters. An Illumina office building is shown in San Diego, California, U.S.,October 20, 2023. REUTERS/Mike Blake/File photo

By Diane Bartz and Mike Scarcella

(Reuters) -A U.S. appeals court on Friday struck down a Federal Trade Commission order against Illumina (NASDAQ:)’s purchase of cancer diagnostic test maker Grail, a former subsidiary, saying the agency had applied a wrong legal standard.

The New Orleans-based panel of the 5th U.S. Circuit Court of Appeals issued a 34-page order that will require the FTC to reconsider the deal.

The three-judge panel said the agency had substantial evidence to show the deal would lessen competition as companies seek to bring to market a blood test to detect many kinds of cancer.

An FTC spokesperson said the panel’s opinion was “an important victory for antitrust enforcement because it clearly recognizes how vertical mergers can threaten competition.”

But the panel also said the FTC failed to properly consider Illumina’s pledge to continue selling its DNA sequencing services to other firms. Illumina has offered to sign contracts to supply any of Grail’s rivals and to not raise prices.

“We are reviewing the decision,” Illumina said in a comment issued after the ruling.

The court rebuffed Illumina’s argument that the FTC unconstitutionally exercised its powers.

“Illumina’s constitutional challenges to the FTC’s authority are foreclosed by binding Supreme Court precedent,” it wrote.

The FTC spokesperson added that the court’s decision marked “a pivotal moment for those who want to protect open, competitive markets, and a huge win for consumers in the modern economy.”

San Diego-based Illumina had filed the appeal in June after the FTC demanded that it divest Grail, saying that the agency had denied it due process.

Grail, valued at $7.1 billion under Illumina’s deal, is seeking to market a powerful test to diagnose many kinds of cancer from a single blood test, known as a liquid biopsy.

The FTC is concerned that Illumina, the dominant provider of DNA sequencing of tumors and cancer cells that help match patients with the best treatment option, might raise prices or refuse to sell to Grail’s rivals.

The agency filed a complaint aimed at stopping the deal in March 2021, but lost before an FTC administrative law judge. The case went back to FTC commissioners, who reinstated the case. Illumina then took it to an appeals court.

Despite the fight with the FTC, and a similar battle in Europe, Illumina closed the acquisition of Grail in mid-2021.

Europe has since proposed measures for Illumina to unwind its acquisition of Grail. Illumina is arguing it does no business in Europe and therefore the EU competition enforcer has no jurisdiction.

Read the full article here

News Room January 4, 2024 January 4, 2024
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Sabadell explores sale of UK high street bank TSB

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Trump Organization to launch mobile phone service and $499 gold handset

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Oil price falls back as flow of crude through Strait of Hormuz unaffected

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

How the Israel-Iran war may develop

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Crypto group Tron to go public after US pauses probe into billionaire founder

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Playa Hotels & Resorts (NASDAQ:PLYA) Delivers Strong Q4 Numbers By Stock Story

By News Room
Stocks

ON24 (NYSE:ONTF) Posts Better-Than-Expected Sales In Q4 By Stock Story

By News Room
Stocks

Evolent Health shares leap on Q4 earnings beat and upbeat guidance By Investing.com

By News Room
Stocks

Chuy’s (NASDAQ:CHUY) Reports Q4 In Line With Expectations But Stock Drops

By News Room
Stocks

Red River Bancshares raises dividend to $0.09 per share

By News Room
Stocks

Ecolab appoints Microsoft executive to board

By News Room
Stocks

Semilux secures $50 million equity deal with White Lion Capital

By News Room
Stocks

US government debt trajectory to push long-term yields higher, says PIMCO

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?